Primary Immunodeficiency Diseases Group, Department of Clinical Medicine, Institut Perubatan & Pergigian Termaju, Universiti Sains Malaysia, 13200, Kepala Batas, Pulau Pinang, Malaysia.
Paediatric Department, School of Medical Sciences, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan, Malaysia.
J Clin Immunol. 2023 Jul;43(5):999-1006. doi: 10.1007/s10875-023-01463-1. Epub 2023 Mar 7.
Primary immunodeficiency disease (PID) affects various aspects of a patient's life. However, the health-related quality of life (HRQOL) of PID among Malaysian patients is poorly described. This study aimed to determine the quality of life of PID patients and their respective parents.
This cross-sectional study was performed from August 2020 to November 2020. Patients with PID and their families were invited to answer the PedsQL Malay version (4.0) questionnaire, the tool used to assess the HRQOL. A total of 41 families and 33 patients with PID answered the questionnaire. A comparison was performed with the previously published value of healthy Malaysian children.
Parents of respondents recorded a lower mean of total score than the parents of healthy children (67.26 ± 16.73 vs. 79.51 ± 11.90, p-value = 0.001, respectively). PID patients reported lower mean total score to healthy children (73.68 ± 16.38 vs. 79.51 ± 11.90, p-value = 0.04), including the psychosocial domain (71.67 ± 16.82 vs. 77.58 ± 12.63, p-value = 0.05) and school functioning (63.94 ± 20.87 vs. 80.00 ± 14.40, p-value = 0.007). No significant difference of reported HRQOL when comparing between subgroup of PID on immunoglobulin replacement therapy and those without immunoglobulin replacement (56.96 ± 23.58 vs. 65.83 ± 23.82, p-value 0.28). Socioeconomic status was found to be predictive of the lower total score of PedsQL in both parent and children reports.
Parents and children with PID, especially those from middle socioeconomic status, have lower HRQOL and school function impairment than healthy children.
原发性免疫缺陷病(PID)影响患者生活的各个方面。然而,马来西亚 PID 患者的健康相关生活质量(HRQOL)描述甚少。本研究旨在确定 PID 患者及其各自父母的生活质量。
本横断面研究于 2020 年 8 月至 2020 年 11 月进行。邀请 PID 患者及其家属回答 PedsQL 马来语版本(4.0)问卷,该工具用于评估 HRQOL。共有 41 个家庭和 33 名 PID 患者回答了问卷。并与之前发表的健康马来西亚儿童的数值进行了比较。
受访者的父母记录的总分均值低于健康儿童的父母(67.26±16.73 与 79.51±11.90,p 值=0.001)。PID 患者报告的总分均值也低于健康儿童(73.68±16.38 与 79.51±11.90,p 值=0.04),包括心理社会领域(71.67±16.82 与 77.58±12.63,p 值=0.05)和学校功能(63.94±20.87 与 80.00±14.40,p 值=0.007)。在比较接受免疫球蛋白替代治疗和未接受免疫球蛋白替代治疗的 PID 亚组之间,报告的 HRQOL 无显著差异(56.96±23.58 与 65.83±23.82,p 值 0.28)。社会经济地位被发现可预测父母和儿童报告的 PedsQL 总分较低。
PID 患者及其父母,尤其是来自中社会经济地位的患者,其 HRQOL 和学校功能受损程度低于健康儿童。